首页 Home文章正文

freespinsnowagering2022| China Resources Shuanghe: subsidiary Lidocaine Hydrochloride Injection obtained registration certificate

Home 2024年05月08日 00:02 6 editor

China Resources double Crane (600062) announcement on the evening of May 7thFreespinsnowagering2022Recently, the company's subsidiary company, China Resources Shuanghe limin Pharmaceutical (Jinan) Co., Ltd. received the Drug Registration Certificate of Lidocaine Hydrochloride injection issued by the State Drug Administration.

freespinsnowagering2022| China Resources Shuanghe: subsidiary Lidocaine Hydrochloride Injection obtained registration certificate

According to the announcement, lidocaine hydrochloride injection is a local anesthetic and antiarrhythmic drug, which is mainly used for infiltration anesthesia, epidural anesthesia, topical anesthesia (including mucosal anesthesia during video-assisted thoracoscopy or abdominal surgery) and nerve conduction block. it can also be used for ventricular extrasystole and ventricular tachycardia after acute myocardial infarction, as well as digitalis poisoning, cardiac surgery and ventricular arrhythmias caused by cardiac catheters.

Shuanghe limin started the drug imitation work in 2021, submitted an application for listing license to the State Drug Administration on November 3, 2022, received a notice of acceptance on December 9, 2022, and was approved for listing by the State Drug Administration on April 24, 2024. According to the relevant national policies and regulations, the Drug Registration Certificate obtained this time is regarded as passing the consistency evaluation. As of the date of this announcement, Shuanghe limin has invested a total of RMB 371 in generic research on the drug.Freespinsnowagering2022.21 million yuan (unaudited).

A total of 90 enterprises (including Shuanghe limin) have approved the listing of lidocaine hydrochloride injection in China. According to Mine.com, the total sales volume (terminal price) of lidocaine hydrochloride injection in the domestic medical market in 2022 was 881 million yuan. among them, the top five enterprises and their market shares are Shandong Hualu Pharmaceutical 21.84%, Hubei Tiansheng Pharmaceutical 13.32%, Hebei Tiancheng Pharmaceutical 6.88%, Shanghai Hefeng Pharmaceutical 5.69%, Suicheng Pharmaceutical 5.42%.

(article source: China Securities News, China Securities Network)

相关文章

ruby slots